On the other hand, low-BTG2-expressing mast cells stimulate fibroblasts to secrete collagen, forming a rigid tumor niche that impedes the penetration of chemotherapeutic drugs, further exacerbating resistance to treatment. This evidence concerns the gene BTG2 and neoplasm.